CD23 is implicated as a regulator of IgE synthesis. A soluble form of CD23 (sCD23) is released following cleavage by ADAM10 and enhanced sCD23 is correlated with increased IgE. In the CNS, signaling through the kainate receptor (KAR) increases ADAM10. In B cells, activation of KARs produced a significant increase in ADAM10 and sCD23 release as well as an increase in B cell proliferation and immunoglobulin production. In addition, ADAM10 inhibitors reduce IgE synthesis from in vitro cultures of human B cells. Thus, we report for the first time the unique presence of the kainate receptor in B cells and that activation of KARs could serve as a novel mechanism for enhancing B cell activation.
Introduction
CD23 (FCεRII) is a type II integral membrane protein and the low affinity receptor for IgE. Through studies using knock-out and transgenic animals, CD23 has been implicated as a natural, negative regulator of IgE production (Texido et al., 1994; Yu et al., 1994) . Although the mechanism remains unclear, interactions with cell surface CD21 as well as direct signaling by the membrane form of CD23 have both been hypothesized to be responsible for IgE modulation. A soluble monomeric form of CD23 (sCD23) is released following proteolytic cleavage by a disintegrin and metalloprotease 10 (ADAM10) (Weskamp et al., 2006) . Enhanced CD23 cleavage has been shown to correlate with increased IgE production in both mouse and human (Ford et al., 2006; Saxon et al., 1990) . In addition to its effects on allergic disease, sCD23 has been linked to the activation of macrophages, via interaction with CD11b/CD18 or CD11c/CD18, resulting in the release of pro-inflammatory mediators and the onset of inflammatory disease (Lecoanet-Henchoz et al., 1995) .
In view of the recent demonstration that ADAM10 is the primary CD23 sheddase, we searched for agents that would modify ADAM10 activity. The overall purpose was to test the hypothesis that ADAM10 modulation would, by virtue being the CD23 sheddase, result in IgE modulation. Ortiz et al., (2005) showed that when a specific type of glutamate receptor, namely the kainate receptor (KAR), was stimulated with its ligand, ADAM10 mRNA increased. KARs are one of three types of multi-subunit, ionotropic glutamate receptors which are named based upon their preferred pharmacological ligand: α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), N-methyl-D-aspartic acid (NMDA), and kainic acid (KA). KARs are the most recently identified of the three and have been shown to be widely expressed in the central nervous system (CNS) (Chittajallu et al., 1999; Lerma, 2006) , however, little is reported on their presence outside the CNS. Kainic acid, a chemical first isolated from the red algae Digenea simplex, is a potent agonist of KARs and is widely used for the generation of epilepsy in laboratory rodent models due to its ability to cause neuro-inflammation following epilepsy induction (Oprica et al., 2006; Engel et al., 2010; Ramsdell and Stafstrom, 2009; Gupta et al., 2009; Zemlyak et al., 2009 ).
Glutamate, the major excitatory neurotransmitter in the CNS has recently been implicated in a variety of diseases. For example, it has been shown that patients with certain cancers (Eck et al., 1990) , human immunodeficiency virus (HIV) (Eck et al., 1989) , epilepsy (Rainesalo et al., 2004 ), autism (Aitken, 2008 , and certain autoimmune illnesses such as rheumatoid arthritis (RA) (McNearney et al., 2000) , and systemic lupus erythematosus (SLE) (West, 2007) all have elevated levels of glutamate in the periphery. Interestingly, autoimmune disease treatments which include corticosteroid use can also increase peripheral glutamate levels (Borsody and Coco, 2001; Raber, 1998; Eck et al., 1990) . While glutamate receptor signaling has been examined in T cells (Ganor et al., 2003a) and macrophages (Boldyrev Journal of Neuroimmunology 233 (2011) 80-89 
